Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?
Rada P, González-Rodríguez Á, García-Monzón C, Valverde ÁM. · 2020
Read Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver? by Rada P, González-Rodríguez Á, García-Monzón C, Valverde ÁM. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7519685.txt.
Description
Rada and co-authors review lipotoxicity in fatty liver disease and ask if CD36 is a key driver. Non-alcoholic fatty liver disease is the most common chronic liver disease worldwide. It ranges from simple fat buildup to hepatitis, cirrhosis, and liver cancer.
Lipotoxicity starts when fatty acid inflow swamps liver cells. Cells fail to store or export the fat as triglycerides. Stress in the ER, oxidative stress, and inflammation follow. The fatty acid carrier CD36 raises fatty acid uptake in the liver. It helps start fat buildup and may push progression to NASH. Patients show more CD36 in the liver and in blood. Its blood level tracks the grade of liver fat. Targeting CD36 or its regulators may prevent or treat the disease.
Catalog record
| CREATOR | Rada P, González-Rodríguez Á, García-Monzón C, Valverde ÁM. |
|---|---|
| YEAR | 2020 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 81 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |